ClinicalTrials.gg
RecruitingNCT07481747SURMOUNT-1Updated Nov 12, 2026

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, sponsored by Hudson Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hudson Biotech · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,539
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Planned enrollment
3rd of 104
2,539 · median 69
Started
2026
with 36 others
Phase 3
26 of 104
7 open now
Primary completion
2027-02
later than 21 of 78 live
Registered
80th of 104
by date

Among the 104 studies testing tirzepatide in Obesity, this one is the 3rd largest by planned enrollment, is one of 37 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 21 of the 78 other live ones, and was the 80th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

54 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.

Read the detailed description

After screening, eligible participants are randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly by subcutaneous injection using an autoinjector. All participants receive lifestyle counseling focused on a reduced-calorie diet and increased physical activity. The main treatment period is 72 weeks. Participants identified with prediabetes at randomization can continue study treatment for up to 176 weeks (plus follow-up), allowing evaluation of longer-term weight management and time to onset/progression to type 2 diabetes. Safety is monitored throughout, including adverse events and laboratory testing.

03

Conditions studied

  • Obesity
  • Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Keywords

  • Tirzepatide
  • LY3298176
  • dual incretin
  • GIP
  • GLP-1
  • obesity
  • overweight
  • weight management
  • placebo
  • randomized
  • double-blind
  • once-weekly
  • subcutaneous
  • lifestyle intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
  • History of at least one unsuccessful dietary effort to lose weight (self-reported)
  • Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires
  • Age ≥18 years
  • Meets protocol /pregnancy criteria (as applicable) and provides written

Exclusion criteria

Exclusion Criteria:

  • Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetes
  • Recent significant weight change (>5 kg within 3 months prior to screening)
  • Prior/planned bariatric surgery; recent/ongoing endoscopic or device-based obesity therapies
  • Severe renal impairment ( \<30 mL/min/1.73 m²)
  • gastric emptying abnormality or chronic use of drugs that directly affect GI motility
  • History of chronic or acute pancreatitis
  • Clinically significant thyroid abnormalities at screening (e.g., TSH outside protocol range) or anticipated need to initiate thyroid replacement during study
  • Obesity due to other endocrinologic disorders (e.g., Cushing syndrome) or monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome)
  • Significant unstable major depressive disorder/severe psychiatric disorder, lifetime suicide attempt, or concerning suicidality screening (PHQ-9/C-SSRS criteria)
  • Uncontrolled hypertension; recent major cardiovascular events; class IV heart failure
  • Active or significant liver disease or certain elevated liver tests at screening (per protocol thresholds)
  • Elevated calcitonin above protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2
  • Active/untreated or remission \<5 years (with specified exceptions)
  • Any other condition contraindicating GLP-1 receptor agonist therapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,539 participants (estimated)

Study arms

  • Experimental
    Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention

    Drug: Tirzepatide · Drug: Placebo · Behavioral: Reduced-calorie diet

  • Experimental
    Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention

    Drug: Tirzepatide · Drug: Placebo · Behavioral: Reduced-calorie diet

  • Experimental
    Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention

    Drug: Tirzepatide · Drug: Placebo · Behavioral: Reduced-calorie diet

  • Experimental
    Arm 4: Placebo once weekly + lifestyle intervention

    Drug: Tirzepatide · Drug: Placebo · Behavioral: Reduced-calorie diet

Interventions

  • (once-weekly SC injection; doses 5/10/15 mg)

  • DrugPlacebo

    (once-weekly SC injection)

  • BehavioralReduced-calorie diet

    increased physical activity counseling

06

What researchers measure

Primary outcomes

  1. Mean percent change in body weight from randomization

    Time frame: 72 Weeks

  2. Percentage of participants achieving ≥5% body weight reduction from randomization

    Time frame: 72 Weeks

Secondary outcomes

  1. Mean change in body weight

    Mean change in body weight (kg) from randomization (pooled 10 mg and 15mg vs placebo)

    Time frame: 72 Weeks

  2. Changes in cardiometabolic measures in triglycerides

    Time frame: 72 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 12 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 19, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Feb 14, 2027
CompletionEst.
Mar 17, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07481747
Lead sponsor
Hudson Biotech
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Feb 2, 2026
Primary completion
Feb 14, 2027 (estimated)
Completion
Mar 17, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Seni S Lu, Phd
Contact
Seni-Lu@beijing-biotech.com
+86 13076790030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion